Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter

van, Cécile A. C. M.; Mjaaland, Siri; Næss, Lisbeth Meyer; Sarkadi, Julia; Gönczöl, Éva; Korsholm, Karen Smith; Hansen, Jens Munk; Jonge, Jørgen de; Kersten, Gideon; Warner, John T.; Semper, Amanda; Kruiswijk, Corine P.; Oftung, Fredrik

doi:10.4161/hv.28639

Cited by 17 publications

(6 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A surrogate marker in vaccine research is a laboratory measurement or physical sign that is used as a substitute for a clinically meaningful endpoint, often used because the clinical endpoint is difficult to study or wants to be avoided. The availability of correlates of protection can help run immunological trials, saving more than 60% of the time and over 80% of the expense compared to large-scale efficacy trials [108], facilitating the approval process of vaccine candidates [112]. The use of serology testing to evaluate vaccine effectiveness is also conditional on evaluating the diagnostic performance of serological assays and their timelines related to vaccine types.…”

Section: Challenges Related To the Adequate Implementation Of Serosurveys And Seroepidemiology Studiesmentioning

confidence: 99%

The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe

Bonanni

Cantón

Gill

et al. 2021

COVID

View full text Add to dashboard Cite

This review explores and positions the value of serology testing to support current immunization policies and the broader policy response to the coronavirus disease 2019 (COVID-19) crisis in Europe. We applied an exploratory approach to analysing existing evidence, international recommendations, and national policies using desk research from secondary sources, document analysis, and expert information. Regional and country-level resources from five focus countries were included: France, Germany, Italy, Spain, and the United Kingdom. Seven experts in the fields of COVID-19 immunization, serology testing, seroepidemiology, and vaccine safety and effectiveness studies contributed to the review and convened in two online panel sessions. The paper includes an overview of (1) the impact of the pandemic to date, (2) testing strategies, (3) COVID-19 vaccination policies, (4) lessons on using serology testing to support immunization, (5) current policies and recommendations on the use of a serology testing strategy, and (6) implementation barriers and challenges. Finally, this paper also provides a set of knowledge-based recommendations to advance the effective and timely inclusion of serology testing and resolve impeding knowledge gaps. The recommendations herein are intended to support timely decision-making, raise awareness, guide advocacy initiatives, and inspire future studies.

show abstract

Section: Challenges Related To the Adequate Implementation Of Serosurveys And Seroepidemiology Studiesmentioning

confidence: 99%

The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe

Bonanni

Cantón

Gill

et al. 2021

COVID

View full text Add to dashboard Cite

show abstract

“…Currently, it is the only universally accepted immune correlate of protection against influenza. However, its relevance may vary between different vaccines and target populations [69].…”

Section: Biomarkers Of Protection and Vaccine Efficacymentioning

confidence: 99%

Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers

Kaufmann

Weiner

Maertzdorf

2017

Expert Review of Vaccines

View full text Add to dashboard Cite

The most recent estimates on tuberculosis (TB) morbidity and mortality reveal that the global disease burden is even higher than previously assumed. Better drugs, diagnostics and vaccines are major requirements to control the ongoing TB pandemic. The high complexity of the infectious process and the underlying pathology, however, challenge elucidation of protective immune mechanisms at the various stages towards active TB disease, which need to be understood for rational design of novel intervention measures. Areas covered: Next to the more classical approaches, host biomarkers increasingly receive attention as promising tools on our way to control the disease. In the area of diagnosis, host biomarkers are recognized as promising new means because the identification of small biosignatures with high discriminatory and even prognostic potential has stimulated the hope that rapid and easy-to-perform diagnosis and prognosis will become possible in the near future. For rational design of new vaccine candidates, correlates of protection are highly desirable. High-throughput systems-vaccinology will boost the identification of such biomarker profiles. Expert commentary: Considering their potential to accelerate development of better diagnostics and vaccines, host biomarkers should be firmly integrated into future TB research.

show abstract

“…However, current correlates of protection (CoP) for influenza vaccines are all based on the induction of antibodies, such as the presence of hemagglutination inhibition- or virus neutralization titers, which are inadequate CoPs for T cell-inducing vaccines. Instead, responses that indicate the presence of effector T cells such as IFN-γ and IL-10 cytokines, combined with cytotoxic effector molecules like granzyme B may be more suitable as CoP for T cell-inducing vaccines ( 81 ). These parameters also need to be further evaluated in epidemiological studies in order to define their efficacy.…”

Section: Preclinical Cellular Correlates Of Protectionmentioning

confidence: 99%

Development of Cross-Protective Influenza A Vaccines Based on Cellular Responses

et al. 2015

Self Cite

View full text Add to dashboard Cite

Seasonal influenza vaccines provide protection against matching influenza A virus (IAV) strains mainly through the induction of neutralizing serum IgG antibodies. However, these antibodies fail to confer a protective effect against mismatched IAV. This lack of efficacy against heterologous influenza strains has spurred the vaccine development community to look for other influenza vaccine concepts, which have the ability to elicit cross-protective immune responses. One of the concepts that is currently been worked on is that of influenza vaccines inducing influenza-specific T cell responses. T cells are able to lyse infected host cells, thereby clearing the virus. More interestingly, these T cells can recognize highly conserved epitopes of internal influenza proteins, making cellular responses less vulnerable to antigenic variability. T cells are therefore cross-reactive against many influenza strains, and thus are a promising concept for future influenza vaccines. Despite their potential, there are currently no T cell-based IAV vaccines on the market. Selection of the proper antigen, appropriate vaccine formulation and evaluation of the efficacy of T cell vaccines remains challenging, both in preclinical and clinical settings. In this review, we will discuss the current developments in influenza T cell vaccines, focusing on existing protein-based and novel peptide-based vaccine formulations. Furthermore, we will discuss the feasibility of influenza T cell vaccines and their possible use in the future.

show abstract

Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter

Cited by 17 publications

References 142 publications

The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe

The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe

Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers

Development of Cross-Protective Influenza A Vaccines Based on Cellular Responses

Contact Info

Product

Resources

About